Correction: Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types

Correction: Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types

Saved in:

Bibliographic Details
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2025-03-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/13/3/e010311corr1.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types
by: Vivek Subbiah, et al.
Published: (2025-02-01)

Authors response to “Letter to the Editor”: “Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types”
by: David R Gandara, et al.
Published: (2025-07-01)

Blood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers
by: Reagan M. Barnett, et al.
Published: (2024-12-01)

Calcium ion-binding genes can predict tumor mutation burden and immune checkpoint blockade response in a pan-cancer model
by: Wan-Yu Lin, et al.
Published: (2025-07-01)

Tumor Immune Response as a Biomarker for Metastasis-Free Survival of Breast Cancer and Immune Checkpoint Inhibition Therapy: A Retrospective Cohort Study
by: Chung-Wu Lin, et al.
Published: (2025-08-01)

Role of tumor mutational burden in patients with urothelial carcinoma treated with immune checkpoint inhibitors: a systematic review and meta-analysis
by: Zhe Wang, et al.
Published: (2025-05-01)

Correction: Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition
Published: (2022-03-01)

Correction: Inhibition of PNCK inflames tumor microenvironment and sensitizes head and neck squamous cell carcinoma to immune checkpoint inhibitors
Published: (2024-11-01)

The impact of immune checkpoint inhibition on atherosclerosis in cancer patients
by: Rui Han, et al.
Published: (2025-07-01)

Mutation of lysine-specific demethylase 5 is associated with enhanced tumor immunity and favorable outcomes in pan-cancer immune checkpoint blockade
by: Xiaofeng Li, et al.
Published: (2024-12-01)

Anion Effect on Phase Separation of Polyethylene Glycol-8000–Sodium Salt Two-Phase Systems
by: Amber R. Titus, et al.
Published: (2024-07-01)

Correction To: High tumor mutational burden assessed through next‑generation sequencing predicts favorable survival in microsatellite stable metastatic colon cancer patients
by: Annabella Di Mauro, et al.
Published: (2025-01-01)

Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung
by: Samuel Kareff, et al.
Published: (2021-02-01)

Immune checkpoint inhibitor‐related type 1 diabetes incidence, risk, and survival association
by: Fumika Kamitani, et al.
Published: (2025-02-01)

IMMUNE CHECKPOINT INHIBITION AND AUTOIMMUNITY: RHEUMATOLOGICAL PROBLEMS
by: E. L. Nasonov
Published: (2018-03-01)

High mutation burden in the checkpoint and micro-RNA processing genes in myelodysplastic syndrome.
by: Ivan Sergeevich Moiseev, et al.
Published: (2021-01-01)

Differential distribution of immune checkpoints across molecular subtypes of colorectal cancer
by: Sofia Edin, et al.
Published: (2025-12-01)

Combination of low-intensity pulsed ultrasound irradiating immune organs with immune checkpoint blockade augments systemic anti-tumor immunity on low tumor burden 4T-1 breast cancer
by: Jixi Li, et al.
Published: (2025-08-01)

Immunogenic chemotherapy sensitizes RAS-mutated colorectal cancers to immune checkpoint inhibitors
by: Lucillia Bezu, et al.
Published: (2023-12-01)

Significance of a Tumor Mutation Burden Gene Signature with Prognosis and Immune Feature of Gastric Cancer Patients
by: Li Xiang, et al.
Published: (2022-01-01)

Scarring alopecia as an unexpected consequence of immune checkpoint inhibition
by: Nelly Kokikian, BS, et al.
Published: (2025-07-01)

Leveraging Tumor Mutation Profiles to Forecast Immune Checkpoint Blockade Resistance in Melanoma, Lung, Head and Neck, Bladder and Renal Cancers
by: Guillaume Mestrallet
Published: (2024-12-01)

Methylation cytometric pretreatment blood immune profiles with tumor mutation burden as prognostic indicators for survival outcomes in head and neck cancer patients on anti-PD-1 therapy
by: Ze Zhang, et al.
Published: (2024-11-01)

Persistent functional and taxonomic groups dominate an 8,000-year sedimentary sequence from Lake Cadagno, Switzerland
by: Paula Rodriguez, et al.
Published: (2025-02-01)

Correction: Associations of concomitant medications with immune-related adverse events and survival in advanced cancers treated with immune checkpoint inhibitors: a comprehensive pan-cancer analysis
Published: (2024-12-01)

Personalized circulating tumor DNA dynamics inform survival and response to immune checkpoint blockade in recurrent/metastatic head and neck cancer
by: Daniel A. Ruiz-Torres, et al.
Published: (2025-08-01)

Mutation of isocitrate dehydrogenase indicates favorable outcomes in pan-cancer immune checkpoint blockade
by: Zhiyang Huang, et al.
Published: (2025-02-01)

Pan-cancer analysis of MET mutation and its association with the efficacy of immune checkpoint blockade
by: Lijin Chen, et al.
Published: (2025-07-01)

Correction: Efficacy of immune checkpoint inhibitors for in-transit melanoma
Published: (2020-10-01)

Case report: Efficacy of immune checkpoint inhibitors for high tumour mutational burden malignant phyllodes tumours of the breast as revealed by comprehensive genomic profiling
by: Hiroo Katsuya, et al.
Published: (2025-02-01)

Unveiling the influence of tumor and immune signatures on immune checkpoint therapy in advanced lung cancer
by: Nayoung Kim, et al.
Published: (2024-11-01)

Immune checkpoint inhibition perturbs neuro-immune homeostasis and impairs cognitive function
by: Onwodi V. Ifejeokwu, et al.
Published: (2025-07-01)

Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition
by: Dirk Schadendorf, et al.
Published: (2021-01-01)

14x8000 : aux sommets de l’impossible, 2021, par Torquil Jones et Gabriel Clarke.
by: Delphine Moraldo
Published: (2022-06-01)

Mechanical HIFU and immune checkpoint inhibition: toward clinical implementation
by: Vera Mekers, et al.
Published: (2024-12-01)

Improved overall survival with checkpoint inhibition and allogeneic transplantation in relapsed Hodgkin lymphoma
by: Nadeem Tabbara, et al.
Published: (2025-03-01)

Inhibition of PNCK inflames tumor microenvironment and sensitizes head and neck squamous cell carcinoma to immune checkpoint inhibitors
by: Ying Li, et al.
Published: (2024-10-01)

Pan‐Cancer Survival Impact of Immune Checkpoint Inhibitors in a National Healthcare System
by: Sean R. Miller, et al.
Published: (2024-11-01)

Splenic volume as a predictor of survival in cancer patients treated with immune checkpoint inhibitors
by: Yunhua Zhang, et al.
Published: (2025-05-01)

Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancer
by: Qian Zhou, et al.
Published: (2021-12-01)